tbuckley/cabot-search huggingface dataset:
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
Authors: Francesco Mannelli, Sara Bencini, Giacomo Coltro, Giuseppe G. Loscocco, Benedetta Peruzzi, Giada Rotunno, Chiara Maccari, Francesca Gesullo, Miriam Borella, Chiara Paoli, Roberto Caporale, Carmela Mannarelli, Francesco Annunziato, Paola Guglielmelli, Alessandro M. Vannucchi
Journal: American Journal of Hematology (2022)

Prognostic modeling in myelofibrosis (MF) has classically pursued the integration of informative clinical and hematological parameters to separate patients' categories with different outcomes. Modern stratification includes also genetic data from karyotype and mutations. However, some poorly standardized variables, as peripheral blood (PB) blast count by morphology, are still included. In this study, we used multiparameter flow cytometry (MFC) with the aim of improving performance of existing scores. We studied 363 MF patients with available MFC files for PB CD34+ cells count determination at diagnosis. We adapted Ogata score to MF context including 2 parameters: absolute CD34+ cells count (/μL) and granulocytes to lymphocytes SSC ratio. A score of 1 was attributed to above-threshold values of each parameter. Accordingly, patients were categorized as MFClow (score = 0, 62.0%), MFCint (score = 1, 29.5%), and MFChigh (score = 2, 8.5%). MFClow had significantly longer median OS (not reached) compared to MFCint (55 months) and MFChigh (19 months). We integrated MFC into established models as a substitute of morphological PB blasts count. Patients were reclassified according to MFC-enhanced scores, and concordance (C-) indexes were compared. As regards IPSS, C-indexes were 0.67 and 0.74 for standard and MFC-enhanced model, respectively (Z score - 3.82; p = 0.0001). MFC-enhanced MIPSS70+ model in PMF patients yielded a C-index of 0.78, outperforming its standard counterpart (C-index 0.73; Z score - 2.88, p = 0.004). Our data suggest that the incorporation of MFC-derived parameters, easily attainable from standard assay used for CD34+ cells determination, might help to refine the current prognostic stratification models in myelofibrosis.
26MO Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
Authors: S. Sun, A. Prelaj, C. Baik, X. Le, M. Garassino, M. Wollner, E. Haura, Z. Piotrowska, M. Socinski, L. Dreiling, G. Bhat, F. Lebel, R. Cornelissen
Journal: Annals of Oncology (2022)
COMPARISONS OF CLINICAL OUTCOMES IN PATIENTS WITH RECURRENT PERICARDITIS BY ETIOLOGIES
Authors: Gauranga Mahalwar, Ankit Agrawal, Ashwin Kumar, Abdullah Yesilyaprak, Felix Berglund, Muhammad Furqan, Nicholas Chan, Bryce Montane, Mohamed M. Gad, Vardhmaan Jain, Beni Verma, Tom Kai Ming Wang, Christine Louise Jellis, Paul Cremer, Allan L. Klein
Journal: Journal of the American College of Cardiology (2022)
Endothelial Piezo1 sustains muscle capillary density and contributes to physical activity
Authors: Fiona Bartoli, Marjolaine Debant, Eulashini Chuntharpursat-Bon, Elizabeth L. Evans, Katie E. Musialowski, Gregory Parsonage, Lara C. Morley, T. Simon Futers, Piruthivi Sukumar, T. Scott Bowen, Mark T. Kearney, Laeticia Lichtenstein, Lee D. Roberts, David J. Beech
Journal: Journal of Clinical Investigation (2022)

Piezo1 forms mechanically activated nonselective cation channels that contribute to endothelial response to fluid flow. Here we reveal an important role in the control of capillary density. Conditional endothelial cell–specific deletion of Piezo1 in adult mice depressed physical performance. Muscle microvascular endothelial cell apoptosis and capillary rarefaction were evident and sufficient to account for the effect on performance. There was selective upregulation of thrombospondin-2 (TSP2), an inducer of endothelial cell apoptosis, with no effect on TSP1, a related important player in muscle physiology. TSP2 was poorly expressed in muscle endothelial cells but robustly expressed in muscle pericytes, in which nitric oxide (NO) repressed the Tsp2 gene without an effect on Tsp1. In endothelial cells, Piezo1 was required for normal expression of endothelial NO synthase. The data suggest an endothelial cell–pericyte partnership of muscle in which endothelial Piezo1 senses blood flow to sustain capillary density and thereby maintain physical capability.
Abstract P5-13-31: Pik3ca mutations and myc amplification are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment
Authors: Qiyun Shi, Juncheng Xuhong, Jia Ge, Feng Liu, Yang Lan, Yi Zhang, Luo Tao, Xiuwu BIan, Xiaowei Qi, Jun Jiang
Journal: Cancer Research (2022)

Abstract Background: Our previous study reported a good efficacy and safety of pyrotinib combined with trastuzumab neoadjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients. We further explored the potential biomarkers for the efficacy of pyrotinib combined with trastuzumab neoadjuvant treatment in HER2-positive breast cancer patients. Methods:To date, a total of 162 patients with early-stage breast cancer were enrolled for the neoadjuvant pyrotinib combined with trastuzumab treatment clinical trial (ChiCTR1900022293). By the method of 425 genes next-generation sequencing (NGS), the genomic characteristics of them were evaluated for the potential correlation with postoperative pathological complete response (pCR). Results:. Among the cohort of 162 cases, a total of 43 patients have completed the whole therapy as well as final surgery and acquired qualified sequencing analysis report, and 25 of them achieved total pCR. The most frequently mutated driver genes were TP53 (80%), PIK3CA (46%), ERBB2 (10%), NF1 (8%), NBN (8%), ATRX (8%), respectively. In terms of somatic copy number alterations, the most frequent alterations are gain or amplification of ERBB2 (66%), MYC (24%), CKD12 (14%), CCND1 (12%) and ZNF217 (12%), respectively. The median tumor mutation burden (TMB) was 4.76 mut/Mb (0.00-29.61). Compared with pCR populations, non-pCR populations had higher median TMB but not statistically significant (5.29 vs 3.85 mut/Mb, P=0.141). In addition, the pCR rate of patients with wild-type PIK3CA is significantly higher than that of patients with mutated PIK3CA (80.0% vs 27.8%, P = 0.001), and those with amplified MYC are more likely to achieve pCR (22.2% vs 67.6%, P = 0.023). Conclusions:Preliminary results suggested that HER2-positive breast cancer patients with activating mutations in PIK3CA and amplified MYC are less likely to benefit from pyrotinib combined with trastuzumab neoadjuvant therapy, which need larger sample size to validate. Citation Format: Qiyun Shi, Juncheng Xuhong, Jia Ge, Feng Liu, Yang Lan, Yi Zhang, Luo Tao, Xiuwu BIan, Xiaowei Qi, Jun Jiang. Pik3ca mutations and myc amplification are associated with pathological complete response in human epidermal growth factor receptor 2-positive breast cancer patients receiving pyrotinib combined with trastuzumab neoadjuvant treatment [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-13-31.
UTILITY OF A MACHINE LEARNING ALGORITHM TO INCREASE PHYSICIAN TRAINEE CONFIDENCE IN AND USAGE OF POINT-OF-CARE ECHOCARDIOGRAPHY
Authors: Carly Waldman, Robert Tickes, Megan Pelter, Stacy Tsai, Kristen Billick, Orendain Natalia, Lilliana Osuna, Samantha Bagsic, Michael R. Smith, David S. Rubenson, Amitabh C. Pandey
Journal: Journal of the American College of Cardiology (2022)
Extracorporeal Kidney-Replacement Therapy for Acute Kidney Injury
Authors: Stéphane Gaudry, Paul M. Palevsky, Didier Dreyfuss
Journal: New England Journal of Medicine (2022)

Acute kidney injury can be accompanied by life-threatening electrolyte and metabolic abnormalities. Kidney-replacement therapy may be urgently needed to prevent death from uremia. This review considers treatment approaches, indications, and intensity in critically ill patients with AKI.
ADAPTing to a New Era of Comparative Effectiveness Research in Traumatic Brain Injury—Generating Evidence From Observational Data
Authors: Geoffrey T. Manley, Hester F. Lingsma, Andrew I. R. Maas
Journal: JAMA Network Open (2022)

Patrick M. Kochanek, MD; P. David Adelson, MD; Bedda L. Rosario, PhD; James Hutchison, MD; Nikki Miller Ferguson, MD; Peter Ferrazzano, MD; Nicole O'Brien, MD; John Beca, MD; Ajit Sarnaik, MD; Kerri LaRovere, MD; Tellen D. Bennett, MD, MS; Akash Deep, MD; Deepak Gupta, MCH, PhD; F. Anthony Willyerd, MD; Shiyao Gao, PhD; Stephen R. Wisniewski, PhD; Michael J. Bell, MD; ADAPT Investigators; Shruti Agarwal; Sarah Mahoney; Laura Loftis; Kevin Morris; Lauren Piper; Anthony Slater; Karen Walson; Todd Kilbaugh; AM Iqbal O'Meara; Nathan Dean; Jessica Carpenter; Ranjit Chima; Brad Kurowski; Enno Wildshut; Naomi Ketharanathan; Mark Peters; Robert Tasker; Joan Balcells; Courtney Robertson; Sian Cooper; Sarah Murphy; Michael Whalen; John Kuluz; Warwick Butt; Neal Thomas; Sandra Buttram; Simon Erickson; J. Mahil Samuel; Rachel Agbeko; Richard Edwards; Iain Macintosh; Michele Kong; Joanne Natale; Heather Siefkes; Christopher Giza; Hari Thangarajah; David Shellington; Anthony Figaji; Elizabeth Newell; Edward Truemper; Sidharth Mahapatra; Robert Clark; Alicia Au; Sue Beers; Christopher Newth; Nadeem Shafi; Alino Nico West; Darryl Miles; Michelle Schober; Truc Le; Jerry Zimmerman; Mark Wainwright; Monica Vavilala; Stuart Friess; Jose Pineda
3 YEAR OUTCOMES OF TRANSCATHETER MITRAL VALVE-IN-VALVE, VALVE-IN-RING AND VALVEIN-MITRAL ANNULAR CALCIFICATION: RESULTS FROM THE MITRAL TRIAL
Authors: Mayra E. Guerrero, Mackram F. Eleid, Dee Dee Wang, Amit Pursnani, Susheel K. Kodali, Issac George, Igor Palacios, Hyde Russell, Raj R. Makkar, Saibal Kar, None Kar, Lowell F. Satler, Vivek Rajagopal, George Dangas, Gilbert Tang, Mark Reisman, Brian K. Whisenant, Kenith Fang, Richard W. Smalling, Tatiana Kaptzan, Bradley Lewis, Pamela Douglas, Jeremy Thaden, Jae K. Oh, William W. O’Neill, Charanjit S. Rihal
Journal: Journal of the American College of Cardiology (2022)
Aβ-responsive metformin-based supramolecular synergistic nanodrugs for Alzheimer's disease via enhancing microglial Aβ clearance
Authors: Zhongxiong Fan, Tong Ren, Youjun Wang, Hao Jin, Dao Shi, Xiaofeng Tan, Dongtao Ge, Zhenqing Hou, Xin Jin, Lichao Yang
Journal: Biomaterials (2022)
EFFECT OF WIRE-JAILING AT SIDE BRANCH IN ONE-STENT STRATEGY FOR CORONARY BIFURCATION LESIONS
Authors: Seung-Jun Lee, Yeon-Jik Choi, Byeong-Keuk Kim, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Soon Jun Hong, Joon Hyung Doh, Young Bin Song, Bon Kwon Koo, Hyeon Cheol Gwon, Chang-Wook Nam, Myeong-Ki Hong, Yang Soo Jang
Journal: Journal of the American College of Cardiology (2022)
IN-VITRO EFFECT OF SHOCKWAVE INTRAVASCULAR LITHOTRIPSY ON CORONARY DRUG-ELUTING STENT POLYMER VISUALIZED BY SCANNING ELECTRON MICROSCOPY
Authors: Adriana Martin, Muhammad Ajmal, Emily Cendrowski, Dominique M. Giesler, Jennifer Iacobini, Deepak Acharya, Michel Corban, Kwan S. Lee
Journal: Journal of the American College of Cardiology (2022)
Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease
Authors: Jia-Jin Chen, Chao-Yi Wu, Chang-Chyi Jenq, Tao-Han Lee, Chung-Ying Tsai, Hui-Tzu Tu, Yu-Tung Huang, Chieh-Li Yen, Tzung-Hai Yen, Yung-Chang Chen, Ya-Chung Tian, Chih-Wei Yang, Huang-Yu Yang
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Glucagon-like peptide-1 (GLP-1) receptor agonist use is associated with reduced mortality and improved cardiovascular outcomes in the general population with diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used antidiabetic agents for patients with advanced-stage chronic kidney disease (CKD). The association of these 2 drug classes with outcomes among patients with diabetes and advanced-stage CKD or end-stage kidney disease (ESKD) is not well understood. <h3>Objective</h3> To assess whether use of GLP-1 receptor agonists in a population with diabetes and advanced-stage CKD or ESKD is associated with better outcomes compared with use of DPP-4 inhibitors. <h3>Design, Setting, and Participants</h3> This retrospective cohort study used data on patients with type 2 diabetes and stage 5 CKD or ESKD obtained from the National Health Insurance Research Database of Taiwan. The study was conducted between January 1, 2012, and December 31, 2018. Data were analyzed from June 2020 to July 2021. <h3>Exposures</h3> Treatment with GLP-1 receptor agonists compared with treatment with DPP-4 inhibitors. <h3>Main Outcomes and Measures</h3> All-cause mortality, sepsis- and infection-related mortality, and mortality related to major adverse cardiovascular and cerebrovascular events were compared between patients treated with GLP-1 receptor agonists and patients treated with DPP-4 inhibitors. Propensity score weighting was used to mitigate the imbalance among covariates between the groups. <h3>Results</h3> Of 27 279 patients included in the study, 26 578 were in the DPP-4 inhibitor group (14 443 [54.34%] male; mean [SD] age, 65 [13] years) and 701 in the GLP-1 receptor agonist group (346 [49.36%] male; mean [SD] age, 59 [13] years). After weighting, the use of GLP-1 receptor agonists was associated with lower all-cause mortality (hazard ratio [HR], 0.79; 95% CI, 0.63-0.98) and lower sepsis- and infection-related mortality (HR, 0.61; 95% CI, 0.40-0.91). Subgroup analysis demonstrated a lower risk of mortality associated with use of GLP-1 receptor agonists compared with DDP-4 inhibitors among patients with cerebrovascular disease (HR, 0.33; 95% CI, 0.12-0.86) than among those without cerebrovascular disease (HR, 0.89; 95% CI, 0.71-1.12) (<i>P </i>=<i> </i>.04 for interaction). <h3>Conclusions and Relevance</h3> Treatment with GLP-1 receptor agonists was associated with lower all-cause mortality among patients with type 2 diabetes, advanced-stage CKD, and ESKD than was treatment with DPP-4 inhibitors. Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD.
THERMODILUTION CARDIAC INDEX IS MORE STRONGLY ASSOCIATED WITH 1-YEAR OUTCOMES THAN MEASURED FICK CARDIAC INDEX IN PATIENTS WITH HFREF: IS IT TIME TO ABANDON THE GOLD STANDARD?
Authors: Nishant Jain, Daniel Perry, Vaiibhav Patel, Carmel Ashur, Victor Moles, Keith D. Aaronson, Gillian Grafton, Todd M. Koelling, Thomas Cascino
Journal: Journal of the American College of Cardiology (2022)
LONG-TERM OUTCOMES ON SAFETY AND EFFICACY OF LEFT ATRIAL APPENDAGE OCCLUSION IN END STAGE RENAL DISEASE PATIENTS UNDERGOING DIALYSIS- THE FIRST MULTICENTER ASIAN EXPERIENCE
Authors: Sheng-Nan Chang, Chin-Feng Tsai, Jung-Cheng Hsu, Hsiao-Liang Cheng, Li-Ting Ho, Pang-Shuo Huang, Jien-jiun Chen, Yi-Chih Wang, Juey-Jen Hwang, Chia-Ti Tsai
Journal: Journal of the American College of Cardiology (2022)
Identification of Novel Loci Shared by Juvenile Idiopathic Arthritis Subtypes Through Integrative Genetic Analysis
Authors: Jin Li, Yun R. Li, Joseph T. Glessner, Jie Yang, Michael E. March, Charlly Kao, Courtney N. Vaccaro, Jonathan P. Bradfield, Junyi Li, Frank D. Mentch, Hui‐Qi Qu, Xiaohui Qi, Xiao Chang, Cuiping Hou, Debra J. Abrams, Haijun Qiu, Zhi Wei, John J. Connolly, Fengxiang Wang, James Snyder, Berit Flatø, Susan D. Thompson, Carl D. Langefeld, Benedicte A. Lie, Jane E. Munro, Carol Wise, Patrick M. A. Sleiman, Hakon Hakonarson
Journal: Arthritis & Rheumatology (2022)

Juvenile idiopathic arthritis (JIA) is the most common chronic immune-mediated joint disease among children and encompasses a heterogeneous group of immune-mediated joint disorders classified into 7 subtypes according to clinical presentation. However, phenotype overlap and biologic evidence suggest a shared mechanistic basis between subtypes. This study was undertaken to systematically investigate shared genetic underpinnings of JIA subtypes.
Treatment of a genetic brain disease by CNS-wide microglia replacement
Authors: Yohei Shibuya, Kevin K. Kumar, Marius Marc-Daniel Mader, Yongjin Yoo, Luis Angel Ayala, Mu Zhou, Manuel Alexander Mohr, Gernot Neumayer, Ishan Kumar, Ryo Yamamoto, Paul Marcoux, Benjamin Liou, F. Chris Bennett, Hiromitsu Nakauchi, Ying Sun, Xiaoke Chen, Frank L. Heppner, Tony Wyss-Coray, Thomas C. Südhof, Marius Wernig
Journal: Science Translational Medicine (2022)

Hematopoietic cell transplantation after myeloablative conditioning has been used to treat various genetic metabolic syndromes but is largely ineffective in diseases affecting the brain presumably due to poor and variable myeloid cell incorporation into the central nervous system. Here, we developed and characterized a near-complete and homogeneous replacement of microglia with bone marrow cells in mice without the need for genetic manipulation of donor or host. The high chimerism resulted from a competitive advantage of scarce donor cells during microglia repopulation rather than enhanced recruitment from the periphery. Hematopoietic stem cells, but not immediate myeloid or monocyte progenitor cells, contained full microglia replacement potency equivalent to whole bone marrow. To explore its therapeutic potential, we applied microglia replacement to a mouse model for Prosaposin deficiency, which is characterized by a progressive neurodegeneration phenotype. We found a reduction of cerebellar neurodegeneration and gliosis in treated brains, improvement of motor and balance impairment, and life span extension even with treatment started in young adulthood. This proof-of-concept study suggests that efficient microglia replacement may have therapeutic efficacy for a variety of neurological diseases.
WIDE QRS COMPLEX TACHYCARDIA IN A PATIENT WITH ATRIAL FIBRILLATION: THE USE DEPENDENCE EFFECT OF FLECAINIDE UNMASKED IN A SYMPTOMATIC FEMALE
Authors: Ebubechukwu Ezeh, Morgan K. Moroi, Mohammad Amro, Mohammed Ruzieh, Omar Salem, Paul I. Okhumale
Journal: Journal of the American College of Cardiology (2022)
STEPWISE APPROACH TO LIPID LOWERING IN ‘VERY HIGH RISK’ PATIENTS UNDERGOING CORONARY ARTERY BYPASS SURGERY: A MONTE CARLO SIMULATION
Authors: Muhammad Adil Sheikh, Salil V. Deo, Peter Ueda, Salah Altarabsheh, Yakov Elgudin, Joseph Rubelowsky, Brian Cmolik, Neil Hawkins, David McAllister, Naveed Sattar, Jill Pell
Journal: Journal of the American College of Cardiology (2022)
Abstract P3-13-07: A comprehensive germline genetic landscape in young Jewish &amp; Arab women with breast cancer
Authors: Gad Rennert, Bita Nehoray, Flavio Lejbkowicz, Sara Dishon, Shiri Kalet, Joseph Herzog, Thomas Slavin, Danielle Castillo, Kevin Tsang, Sharon Sand, Hedy S Rennert, Jeffrey Weitzel
Journal: Cancer Research (2022)

Abstract Background: After decades of research on Ashkenazi Jewish (AJ) founder mutations in BRCA1 and BRCA2 (BRCA), there is still little known about genetics in non-AJ and Arab breast cancer populations in Israel and non-BRCA pathogenic variants (PV) in the total population. We used multigene panel testing (MGPT) to characterize the spectrum and prevalence of PV in cancer susceptibility genes in various Jewish and Arab demographic subgroups. Methods: A population-based cohort of women diagnosed with breast cancer before the age of 46 in a defined geographical area in Northern Israel was recruited as part of the BCINIS study and underwent MGPT. Probability matrices of proportion of PV by gene, and by ethnic sub-group (AJs, Sephardi Jews of North African origin, Sephardi Jews of other Eastern origins, Arabs), age-sub-group (35 and under, 36-45) and first-degree family history of breast, ovary or pancreatic cancer were calculated. Results: Overall, 1650 women were tested, including 1012 Jewish, 530 Arab and 108 non-Jewish/non-Arab women. We detected 375 PV among 363 women (22.7%): 212 in AJ (33.4% of AJs), 61 in Sephardi Jews (14.2% of Sephardi), and 69 in Arabs (13.0% of Arab). Only 162 of the PV (43.2%) were the BRCA AJ founders, another 39 BRCA PV (10.4%) were reported previously, while 15 BRCA PV (4.0%) are likely private. The remaining non-BRCA PV (42.4%) were distributed across 18 genes, with findings predominantly in CHEK2, MUTYH, ATM, BLM, ERCC3, PALB2, and FANCA. The prevalence of PV varied significantly across the ancestral subsets, from 95.5% probability in AJ women diagnosed before age 36 and with first degree family history to only 9.3% in Arab women diagnosed at age 36-45 and without family history. Conclusions: In this comprehensive, population-based, cohort of women with young onset breast cancer, the presence of PV in more than 15 genes is compelling and informs a necessarily broader approach to genetic testing and counseling. Citation Format: Gad Rennert, Bita Nehoray, Flavio Lejbkowicz, Sara Dishon, Shiri Kalet, Joseph Herzog, Thomas Slavin, Danielle Castillo, Kevin Tsang, Sharon Sand, Hedy S Rennert, Jeffrey Weitzel. A comprehensive germline genetic landscape in young Jewish &amp; Arab women with breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-13-07.
A RARE CASE OF VERAPAMIL RESISTANT IDIOPATHIC LEFT FASCICULAR VENTRICULAR TACHYCARDIA
Authors: Kalpeshkumar Shah, Aditya Patel, Biren D. Patel, Kinjal D. Patel, Ahmad Damati, Joaquim Jose Correia, Fayez E. Shamoon
Journal: Journal of the American College of Cardiology (2022)
NATURAL AND MODIFIED HISTORY OF ATRIOVENTRICULAR VALVE REGURGITATION IN PATIENTS WITH FONTAN CIRCULATION: IMPACT OF RIGHT VENTRICULAR DOMINANCE
Authors: Greg King, Edward Buratto, David Celermajer, Leeanne Grigg, Nelson Alphonso, Terry Robertson, Andrew M. Bullock, Julian Ayer, AJay Iyengar, Yves d'Udekem, Igor Konstantinov
Journal: Journal of the American College of Cardiology (2022)